ClinicalTrials.gg
RecruitingNCT06562361Updated Aug 29, 2024

A Microdose Trial Investigating Binding of [68Ga]Ga-DOTA-CYS-ATH001 in Healthy Subjects and Different Patient Groups.

An Early Phase 1 interventional study of [68Ga]Ga-DOTA-Cys-ATH001 in MASH, PSC and Fibrostenotic Crohn's Disease, sponsored by Antaros Medical. Recruiting at 3 sites in Sweden. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Antaros Medical · Early Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Crohn Disease with a site in Sweden — 12 open to participants now, 20 under way, 8 of them phase 3. Crohn Disease · Sweden.

Planned enrollment
47th of 58
30 · median 398
Started
2024
with 4 others
Phase 1
3 of 67
1 open now
Primary completion
2025-12
later than 1 of 19 live
Registered
58th of 67
by date

Among the 67 studies in Crohn Disease with a site in Sweden, this one is the 47th largest by planned enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2024, is one of 3 in phase 1, reaches primary completion later than 1 of the 19 other live ones, and was the 58th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

12 of the 67 studies in Crohn Disease with a site in Sweden are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Crohn Disease with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this clinical trial is to use positron emission tomography (PET) to evaluate and compare the binding of the novel tracer [68Ga]Ga-DOTA-Cys-ATH001 in the liver and/or gastrointestinal tract between healthy volunteers and different patient groups including patients with metabolically caused steatohepatitis (MASH), patients with fibrostenotic Crohn´s Disease (CD) and patients with primary sclerosing cholangitis (PSC).The study will also assess the safety of a microdose of 68Ga]Ga-DOTA-Cys-ATH001 and how it is distributed in different parts of the body. The main questions the study aims to answer are:

  • What does the uptake of the [68Ga]Ga-DOTA-Cys-ATH001 PET-tracer look like in the liver of healthy subjects, and in that of patients with MASH and PSC?
  • What does the uptake of the [68Ga]Ga-DOTA-Cys-ATH001 PET-tracer look like in the GI tract of healthy subjects, and that of patients with fibrostenotic CD?
  • How much [68Ga]Ga-DOTA-Cys-ATH001 PET-tracer can be found in the blood after injection?
  • How is [68Ga]Ga-DOTA-Cys-ATH001 uptake distributed in the body?
  • What medical problems do participants have when receiving [68Ga]Ga-DOTA-Cys-ATH001?

Participants will:

Receive one administration of [68Ga]Ga-DOTA-Cys-ATH001, after which examination with PET is performed. Magnetic Resonance Imaging (MRI) is also used in the study to create a detailed picture of the body and its function which will facilitate the interpretation of the results of the PET examination. A subset of participants will have blood samples collected after the tracer administration to assess the blood levels of the tracer over time.

A subset of participants will come back for a second visit where they will receive a second administration of [68Ga]Ga-DOTA-Cys-ATH001, followed by PET and MRI.

A health check-up is performed before dosing, and a safety assessment will be performed after dosing. A remote follow-up visit is performed the day after the dosing visit.

Read the detailed description

This is a first-in-human (FIH), phase 0, multi-center, non-randomized trial to investigate [68Ga]Ga-DOTA-Cys-ATH001 PET-tracer binding in the liver and in the GI tract in healthy subjects and patients with metabolically caused steatohepatitis (MASH), patients with fibrostenotic Crohn´s Disease (CD) and patients with primary sclerosing cholangitis (PSC), in a total of 5 different cohorts, including a sub-trial to assess test-retest reliability and a sub-trial to assess dosimetry. The allocation of cohorts is:

  • Cohort 1a (n=3): Healthy volunteers, sub-group dosimetry,
  • Cohort 1b (n=3): Healthy volunteers, sub-group test/retest,
  • Cohort 2a (n=3): Presumed MASH patients, sub-group dosimetry,
  • Cohort 2b (n=3): Presumed MASH patients, sub-group test/retest,
  • Cohort 3 (n=6): Verified MASH patients,
  • Cohort 4 (n=6): Fibrostenotic CD patients,
  • Cohort 5 (n=6): PSC patients.

The participants will come for 2 or 3 visits to the trial site. The screening (Visit 1) will include an eligibility check and review of health status. Participants in cohort 2 and cohort 3 will perform a FibroScan® investigation.

At Visit 2, participants will come to the trial site for PET/MRI and safety assessments. The participants will receive a single, bolus iv injection of a maximum of 100 µg [68Ga]Ga-DOTA-Cys-ATH001 after which participants will be examined by whole-body PET/MRI scans. A sub-group of participants in cohort 1 (cohort 1a, healthy subjects, n=3, the first 3 participants in this cohort) and cohort 2 (cohort 2a, presumed MASH patients, n=3, the first 3 participants in this cohort) will be participating in a sub-trial to calculate the whole-body dosimetry of the tracer. These participants will have one longer PET visit and will be examined by sequential whole-body PET/MRI scans to determine tracer biodistribution and clearance. At Visit 4 (within 6 weeks of Visit 2), participants taking part in the test/retest sub-trial (Cohorts 1b and 2b) will come for a second PET/MRI visit which includes a second administration of [68Ga]Ga-DOTA-Cys-ATH001.

To determine tracer clearance from blood, venous (1a and b and 2a and b) and arterial (1b and 2b) PK samples will be collected post-dose. No PK samples will be taken from cohorts 3 to 5.

Safety assessments will take place after the PET/MRI (vital signs, 12-lead ECG, safety laboratory sampling and injection site reactions). A remote follow-up by telephone (Visit 3) will be performed the day after [68Ga]Ga-DOTA-Cys-ATH001 dosing to follow-up on AEs, injection site reactions and concomitant medication.For participants in cohorts 1b and 2b (the test/retest sub-group), a remote follow-up by telephone (Visit 5) will be performed the day after [68Ga]Ga-DOTA-Cys-ATH001 dosing to follow-up on AEs, injection site reactions and concomitant medication.

03

Conditions studied

  • MASH
  • PSC
  • Fibrostenotic Crohn's Disease
  • Healthy Volunteers

Browse trials for

Keywords

  • PET
  • Tracer
  • PDGFRB
  • MASH
  • PSC
  • MRI
  • Crohn´s Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give written for participation in the trial and able to comply with all trial procedures and requirements.
  2. Male or female participant aged 18 to 75 years, inclusive, at the screening visit.
  3. (BMI) ≥ 19 and \< 40.0 kg/m2 at the time of the screening visit.
  4. Women of (WOCBP) must practice abstinence from heterosexual intercourse (only allowed when this is the preferred and usual lifestyle of the participant) or must agree to use a highly effective method of with a failure rate of \< 1 % to prevent pregnancy from at least 2 weeks prior to administration of tracer for at least 1 week after the PET imaging examination (or for at least 1 weak after the last PET imaging examination for those participants undergoing test/retest PET imaging). In addition, any male partner of a female participant must, unless he has undergone vasectomy, agree to use a condom during the same time period.

    The following are considered highly effective methods of contraception:

    • combined (estrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal),
    • progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable),
    • intra-uterine device [IUD]or intra-uterine hormone-releasing system [IUS]) WOCBP must refrain from donating eggs until 3 months after the last tracer administration.

    WOCBP with an exclusive male partner who has undergone vasectomy may choose not to use contraceptives.

    Women of non-childbearing potential are pre-menopausal females who have undergone any of the following surgical procedures; hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, or who are defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle-stimulating hormone [FSH] >25 IU/L is confirmatory).

    Male participants must be willing to use condom or be vasectomized or practice sexual abstinence from heterosexual intercourse (only allowed when this is the preferred and usual lifestyle of the participant) to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the administration of tracer until 3 months after the administration of tracer. Any female partner of a non-vasectomized male participant who is of childbearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy (see above) from at least 2 weeks prior to administration of tracer to 4 weeks after administration of tracer.

    Cohort-specific inclusion criteria:

    Cohort 1 (healthy participants)

  5. Medically healthy participant without abnormal medical history, physical findings, vital signs, , and laboratory values at the time of the screening visit, as judged by the Investigator.

    Cohort 2 (presumed MASH patients) MASH diagnosis based on non-invasive assessments. Participants should have a high level of disease activity with regards to pro-peptide of type III collagen (ProC3) as a marker of ongoing fibrogenesis.

  6. Steatosis according to , radiology, or controlled attenuation parameter (CAP) (≥ 280 dB/M 8), assessments ≤ 24 weeks prior to the screening visit.
  7. At least 1 cardiometabolic criteria from the following list:

    A. BMI ≥ 25 kg/m2 [23 Asia] OR waist circumference (WC) > 94 cm (M) 80 cm (F) OR ethnicity adjusted, B. Fasting serum glucose ≥ 5.6 mmol/L [100 mg/dL] OR 2-hour post-load glucose levels ≥ 7.8 mmol/L [≥ 140 mg/dL] OR ≥ 5.7% [39 mmol/L) OR type 2 diabetes OR treatment for type 2 diabetes, C. Blood pressure ≥ 130/85 mmHg OR specific antihypertensive drug treatment, D. Plasma triglycerides ≥ 1.70 mmol/L [150 mg/dL] OR lipid-lowering treatment, E. Plasma high-density lipoprotein (HDL)-cholesterol ≤ 1.0 mmol/L [40 mg/dL] (M) and ≤ 1.3 mmol/L [50 mg/dL] (F) OR lipid-lowering treatment.

  8. ProC3 ≥ 12.6 ng/mL. Cohort 3 (verified MASH patients) MASH diagnosis based on historical liver biopsy. Participants should have a high level of disease activity with regards to ProC3 as a marker of ongoing fibrogenesis, to allow for correlation to PET-tracer uptake.
  9. Evidence of steatosis according to biopsy, radiology, or CAP (≥ 280 dB/M) or MRI-PDFF, assessments ≤ 24 weeks prior to the screening visit.
  10. At least 1 cardiometabolic criteria from the following list:

    A. BMI ≥ 25 kg/m2 [23 Asia] OR WC > 94 cm (M) 80 cm (F) OR ethnicity adjusted, B. Fasting serum glucose ≥ 5.6 mmol/L [100 mg/dL] OR 2-hour post-load glucose levels ≥ 7.8 mmol/L [≥ 140 mg/dL] OR HbA1c ≥ 5.7% [39 mmol/L) OR type 2 diabetes OR treatment for type 2 diabetes, C. Blood pressure ≥ 130/85 mmHg OR specific antihypertensive drug treatment, D. Plasma triglycerides ≥ 1.70 mmol/L [150 mg/dL] lipid-lowering treatment, E. Plasma HDL-cholesterol ≤ 1.0 mmol/L [40 mg/dL] (M) and ≤ 1.3 mmol/L [50 mg/dL] (F) OR lipid-lowering treatment.

  11. Historical liver biopsy 24 weeks to 4 weeks prior to inclusion with proven metabolic dysfunction-associated steatotic liver disease (MASLD).
  12. ProC3 ≥ 12.6 ng/mL. Cohort 4 (fibrostenotic CD patients)
  13. Fibrostenotic CD as evidenced by persistent luminal narrowing with or without obstructive symptoms as assessed with MRI, ≤ 24 weeks prior to the screening visit OR fibrostenotic CD by positive colonoscopy up to 24 weeks prior to the screening visit.
  14. Crohn's disease activity index (CDAI) \< 150
  15. Calprotectin \< 250
  16. C-reactive protein (CRP) \< 20 Cohort 5 (PSC patients)
  17. Large duct PSC, including intrahepatic bile duct involvement, according to MRI/MRCP.
  18. ProC3 ≥ 12.6 ng/mL

Exclusion criteria

Exclusion Criteria:

  1. Any for MRI according to a standard checklist used in clinical practice, including claustrophobia, metallic implants or internal electrical devices (e.g., cochlear implant, nerve stimulator, gastric pacemaker, bladder stimulator, cardiac pacemaker, defibrillator, artificial valves in heart, aneurysm clips or coils, etc.), inability to stay in supine position for 90 minutes, and permanent makeup or tattoos which in the Investigator's opinion might jeopardize the participant's safety or interfere with the imaging assessments.
  2. Having worked as a metal worker or welder.
  3. History of any disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial or influence the results or the participant's ability to participate in the trial.
  4. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the screening visit.
  5. Any within the past 12 months before the screening visit, with the exception of successfully treated basal cell carcinoma of the skin or in situ prostate cancer under active surveillance, with no interventions scheduled during the period of trial participation.
  6. Any planned major surgery within the duration of the trial participation.
  7. Participants who are pregnant, currently breastfeeding, or intend to become pregnant during the course of the trial.
  8. Any positive result at the screening visit for serum surface antigen, hepatitis B or C antibodies and/or (HIV).
  9. Any chronic active infection (e.g., HIV, Hepatitis B or C, tuberculosis, etc.).
  10. Poor peripheral venous access, as judged by the Investigator.
  11. After 10 minutes of supine rest at the screening visit, any vital signs values outside the following ranges:

    • Systolic blood pressure: \< 90 or >165 mmHg, or
    • Diastolic blood pressure \< 50 or >100 mmHg, or
    • Pulse \< 40 or > 90 bpm
  12. The participant has a change in body weight ≥5%, 3 months before the screening visit.
  13. The participant has any laboratory abnormality or condition that, in the Investigator's opinion, could adversely affect the safety of the participant or impair the assessment of trial results.
  14. Clinically significantly abnormal 12-lead recording result or cardiac symptoms as judged by the Investigator.
  15. The participant is using any prohibited concomitant medications as described in the protocol, at the discretion of the Investigator.
  16. Current use of any hormone therapy at doses that may cause metabolic interference as judged by the Investigator. Stable hormonal replacement therapy is allowed.
  17. Currently participating, or previous participation in another clinical trial within 30 days prior to the screening visit or previous participation in another PET imaging trial within the last 12 months.
  18. Positive screening result for alcohol at the screening visit (cohorts 1a and 1b only).
  19. Ongoing or previous alcohol abuse, or long-standing excessive intake of alcohol, as judged by the Investigator.
  20. Presence or history of drug abuse, as judged by the Investigator.
  21. History of, or current use of anabolic steroids, as judged by the Investigator.
  22. Plasma donation within 1 month of screening or blood donation (or corresponding blood loss) during the last 3 months prior to screening.
  23. The Investigator considers the participant unlikely to comply with trial procedures, restrictions, and requirements.

    Additional exclusion criteria for all participants (cohorts 2-5):

  24. The participant is receiving treatment with vitamin E, thiazolidinediones, or glucagon-like peptide-1 receptor agonists unless on a stable dose for 3 months before the screening Visit and is anticipated to maintain the same dosing regimen throughout trial participation.
  25. Participants with ≥48 mmol/mol (6.5%) at screening without a previous diagnosis of T2D must not take part in the study. Participants with a previous diagnosis of T2D are permitted to enter the study if on a stable regimen of antidiabetic therapy for at least 3 months before screening. Participants who are on a stable regimen of antidiabetic therapy for at least 3 months before screening and have HbA1c of ≥ 63 mmol/mol (9%) at screening should be excluded.
  26. Clinically significant disease, apart from T2D, which in the opinion of the Investigator might interfere with the interpretation of the trial results and/or the safety of the participant, or in any other way unsuitable for participation in this clinical trial.
  27. The participant has a severe immune-mediated inflammatory disease (IMID) (e.g., rheumatoid arthritis, spondylarthritis disease spectrum, connective tissue disorders, cutaneous inflammatory conditions such as psoriasis, atopic dermatitis, hidradenitis suppurativa, asthma, multiple sclerosis). Participants with inactive IMID or active IMID of mild to moderate severity are permitted to enter the trial.

    Additional exclusion criteria for MASH and PSC participants (cohorts 2-3, and 5)

  28. Liver stiffness > 25 kPa by transient elastography or any sign of decompensation. For cohorts 2 and 3, based on the FibroScan® evaluation on the screening visit, and for cohort 5 based on routine elastography performed ≤ 12 months.
  29. For participants with -confirmed fibrosis stage F2 or F3, the participant has any of the following during the screening period:

    • (AST) levels > 5 x the (ULN).
    • Alanine aminotransferase (ALT) levels > 5 x ULN.
    • Alkaline phosphatase (ALP) ≥ 2 x ULN (cohorts 2 and 3) and ALP ≥ 10 (cohort 5).
    • Serum creatinine ≥1.5 x ULN or has an estimated (eGFR) \< 45 mL/min/1.73m2 (the revised Lund-Malmö GFR estimating equation will be used).
    • (INR) >1.3.
    • Total TBL ≥ULN (except for patients with a documented history of Gilbert's syndrome if direct is within the normal reference range).
    • Direct bilirubin ≥ 3 x ULN.
    • count \< 60 x 109/L.
    • Presence or history of ascites, hepatic encephalopathy, or variceal bleeding.
    • Presence or history of > 6 (Class B or C), unless due to therapeutic anticoagulation.
    • Presence or history of Model for End-Stage Liver disease (MELD) score >12 (only for cohorts 2-3).

    Note: It is the Investigator's decision, in consultation with the Sponsor, to allow participants to enter the study who have clinically meaningful rising tendencies in liver chemistries or significantly elevated liver chemistries that do not yet satisfy but could be interpreted as clinically concerning (i.e., AST or ALT > 4 x ULN) at any visit during the screening period.

  30. The participant has a change in body weight ≥ 5% after qualifying liver biopsy. Additional criteria for fibrostenotic CD participants (cohort 4)
  31. MRI findings consistent with only inflammation, i.e., edema, hyperemic intestinal wall, restricted diffusion, mesenteric lymphadenopathy etc.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    100 µg [68Ga]Ga-DOTA-Cys-ATH001 (target dose of 200 MBq)

    All participants will receive a single, bolus iv injection of up to 100 µg \[68Ga\]Ga-DOTA-Cys-ATH001 (target dose of 200 MBq). At Visit 4, cohort 1b (healthy participants, n=3) and cohort 2b (presumed MASH participants, n=3) will come for a second PET/MR imaging visit within 6 weeks from the first imaging visit where an additional bolus iv injection of up to 100 µg \[68Ga\]Ga-DOTA-Cys-ATH001 will be administered.

    Drug: [68Ga]Ga-DOTA-Cys-ATH001

Interventions

  • Target dose of 200MBq \[68Ga\]Ga-DOTA-Cys-ATH001 corresponding to a maximum mass dose of 100 µg, administered as an intravenous bolus dose.

06

What researchers measure

Primary outcomes

  1. [68Ga]Ga-DOTA-Cys-ATH001 uptake in the whole liver of healthy subjects compared with patients with MASH and PSC

    Difference in \[68Ga\]Ga-DOTA-Cys-ATH001 mean standardized uptake value (SUV) in the whole liver of healthy subjects (cohort 1), compared with patients with MASH (cohort 2 and 3) and PSC patients (cohort 5).

    Time frame: Assessed during the intervention

  2. [68Ga]Ga-DOTA-Cys-ATH001 uptake in the GI tract of healthy subjects compared with patients with fibrostenotic CD

    Difference in \[68Ga\]Ga-DOTA-Cys-ATH001 SUV in the GI tract of healthy subjects (cohort 1) compared with patients with fibrostenotic CD (cohort 4).

    Time frame: Assessed during the intervention

Secondary outcomes

  1. [68Ga]Ga-DOTA-Cys-ATH001 PET-tracer PK in arterial and venous plasma

    \[68Ga\]Ga-DOTA-Cys-ATH001 PET-tracer PK (radioactivity associated with the parent compound) in arterial and venous plasma for up to 125 minutes after injection.

    Time frame: Assessed 5 minutes to 125 minutes post-dose

Other outcomes

  1. Whole-body dosimetry of [68Ga]Ga-DOTA-Cys-ATH001 PET tracer in healthy subjects and patients with presumed MASH.

    Whole-body dosimetry of \[68Ga\]Ga-DOTA-Cys-ATH001 PET tracer in healthy subjects (cohort 1a) and patients with presumed MASH (cohort 2a).

    Time frame: Assessed during the intervention

  2. Safety of [68Ga]Ga-DOTA-Cys-ATH001 PET tracer

    Safety of \[68Ga\]Ga-DOTA-Cys-ATH001 PET tracer as assessed by * Frequency of, seriousness, and intensity of AEs. * Frequency of clinically significant changes in vital signs, ECG, safety laboratory measurements (hematology, clinical chemistry, coagulation, and urinalysis) and physical examination findings. * Frequency of injection site reactions.

    Time frame: Assessed up to 48 hours post intervention

07

Study locations

1 of 3 sites recruiting
  • CTC Karolinska
    Stockholm, SE-171 64 S, Sweden
    Recruiting
    • Kaveh Azizi, MD · Contactkaveh.azizi@ctc-ab.se · +46 (0)76 140 56 21
    • Kaveh Azizi, MD · Principal investigator
  • CTC Akademiska Uppsala University Hospital, Entrance 85, 2nd level
    Uppsala, SE-751 85, Sweden
    Not yet recruiting
    • Erik Rein-Hedin, MD · Contacterik.rein-hedin@ctc-ab.se · +46 (0)70 755 20 89
    • Erik Rein-Hedin, MD · Principal investigator
  • Section of Gastroenterology/Hepatology, Uppsala University Hospital
    Uppsala, SE-751 85, Sweden
    Not yet recruiting
    • Johan Vessby, MD, PhD · Contactjohan.vessby@akademiska.se · +46 (0)73 356 93 04
    • Fredrik Rorsman, MD, PhD · Sub investigator
    • Eva-Lena Syren, MD · Sub investigator
    • Kajsa Björner, MD · Sub investigator
    • Johan Vessby, MD, Phd · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Dec 2025, 16 months later.

Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 16 months is close to that.

Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 20, 2024
StartEst.
Aug 2024
Primary completionEst.
Dec 2025
CompletionEst.
Mar 2026
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06562361
Lead sponsor
Antaros Medical
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Aug 2024 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
Aug 29, 2024

Study contacts

Johan Vessby, MD, PhD
Contact
johan.vessby@akademiska.se
+46 (0)73 356 93 04
Johan Vessby
principal investigator · Section of Gastroenterology/Hepatology SE-751 85 Uppsala, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion